Table 6.

The main studies describing the effectiveness/limitations of the HA 330 cartridge

	Huang et al. 2010 [56]	Huang et al. 2013 [57]
Study design	RCT	RCT
Study population (n)	44 sepsis or septic shock patients	46 ALI/extra-pulmonary sepsis patients
EAA assessment	–	–
Prescribed dose	HP for 2 h for 3 days	HP for 2 h for 3 days
Survival	• ICU mortality 12.5% in HA vs 45.0% in the controls (p = 0.02) • Hospital mortality 37.5% in HA vs 50.0% in the controls (p = 0.81) • 28-day mortality 45.8% in HA vs 55.0% in controls (p = 0.47)	• ICU mortality 24% in HA vs 57.14% in the controls (p = 0.02) • 28-day mortality 28% in HA vs 66.7% in the controls (p = 0.009)
Length of ICU stay (days)	12.4 ± 3.1 in HA vs 19.5 ± 4.0 in controls (p = 0.03)	15.5 ± 4.0 in HA vs 19.4 ±  3.1 in controls (p = 0.04)
Hemodynamics	Significant reduction in VP dose in the HA group vs increase in the control group (p = 0.01)	Significant reduction in VP dose in the HA group vs increase in the control group (p = 0.032)
Other results	Significant difference in IL-8 and IL-6 levels between the two groups at day 3 (p = 0.03 and 0.01, respectively)	Significant difference in IL-1 and TNF-a in BAL fluid between the two groups (p = 0.02 and 0.04, respectively)
Safety	• 1 patient with fever in the HA group • Transient reduction in platelet counts in the HP group	–

RCT randomized controlled trial, ALI acute lung injury, EAA endotoxin activity assay, HA hemadsorption, HP hemoperfusion, ICU intensive care unit, TNF tumor necrosis factor, BAL broncho-alveolar lavage, VP vasopressor, IL interleukin